C lostridium difficile is one of the most common causes of health care-associated infection in US hospitals, affecting almost 1% of hospitalized patients each year. [1] [2] [3] Since 2000, the incidence of C difficile infection (CDI) has increased more than 200% while the rates of other health care-associated infections have decreased. 1, 2, [4] [5] [6] More than 300 000 hospitalizations involve a CDI each year, at an annual cost of $1.0 to $4.9 billion to the US health care system. 2, 7 Initial increases in the rate of CDI were attributed to the emergence of a novel, hypervirulent strain during a period when at least 95% of hospitals used toxin immunoassays for diagnosis (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) . 3, 5, [8] [9] [10] More recent increases have been linked to greater C difficile detection after the introduction of molecular tests, which are more sensitive and detect microbial DNA instead of toxin. [10] [11] [12] [13] [14] [15] Individual hospitals have reported a 50% to 100% increase in the rate of CDI after switching from toxin tests to molecular tests. 11, 12, 14 Similar increases have been observed in the rate of publicly reported CDI as reporting facilities adopted molecular tests.
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For decades, toxin tests were favored over culture for diagnosis of CDI because toxins mediate disease and toxin detection was faster and provided evidence of toxin production in vivo that typically correlated better with clinical disease.
3,10,16-18 Molecular tests such as polymerase chain reaction (PCR) target toxin genes but are similar to culture in detecting C difficile bacteria regardless of toxin production, making it unclear whether positive PCR results reflect clinical disease. 3, 10, [19] [20] [21] The uncertain clinical significance of positive PCR results is problematic in inpatient health care facilities, where C difficile colonization is 5 to 10 times more common than CDI and noninfectious causes of diarrhea are also common. [22] [23] [24] [25] [26] Nonetheless, concern that patients with CDI were being missed by toxin tests prompted many laboratories to switch to molecular tests in 2009, when they became available. 10, 19, 27 As of the first quarter of 2014, a total of 44% of acute care hospitals participating in the National Healthcare Safety Network (NHSN) reported using molecular tests alone or in combination with other tests for diagnosis of CDI (NHSN, written communication, September 15, 2014). Therefore, there is an urgent need to determine whether patients with negative toxin test results and positive molecular test results have CDI or are simply colonized with another c ause of symptoms.
To address this need, we prospectively tested hospitalized adults with suspected CDI at the University of California Davis Medical Center with molecular tests while maintaining our existing toxin test for clinical diagnosis. We then collected clinical outcome and treatment data to enable us to ask 3 related questions. First, what is the natural history of PCR-positive patients with negative toxin immunoassay results? Second, how do outcomes in these patients compare with outcomes in patients with positive toxin and PCR results or completely negative C difficile test results? Third, do PCR-positive patients with negative toxin results require treatment for CDI?
Methods

Study Design and Population
Hospitalized adults with a diarrheal stool sample submitted for C difficile testing 72 hours or longer after admission to the University of California Davis Medical Center between December 1, 2010, and October 20, 2012, were included in the study. Only the first sample was analyzed for each patient. Samples received after discharge were excluded. Patients with C difficile detected by culture and no other test were excluded from the study. The study protocol was approved by the University of California Davis Institutional Review Board. Informed consent was waived for the initial screening and symptom verification and overall outcome and safety analysis. A subset of patients had written informed consent obtained for additional in-person follow-up.
Laboratory Testing
All stool samples had a US Food and Drug Administration (FDA)-approved C difficile toxin immunoassay (C difficile Premier toxins A and B; Meridian Biosciences) performed and reported clinically. Formed stools were rejected. Eligible samples also had 1 or more FDA-approved molecular C difficile tests (Xpert C. difficile/Epi; Cepheid; and illumigene C. difficile; Meridian Biosciences) performed but not reported, allowing patients to be grouped by C difficile toxin immunoassay and PCR results as toxin immunoassay positive and PCR positive (Tox+/PCR+), Tox−/PCR+, or Tox−/PCR−. Additional tests were performed to characterize the nature of the C difficile colonization and host inflammatory response. The PCR-positive samples had toxin quantitated (xCELLigence System for Real-Time Cellular Analysis, version 2; ACEA Biosciences) and the concentration of C difficile DNA determined as a measure of bacterial load (Xpert C. difficile/Epi; Cepheid). [28] [29] [30] The Tox−/PCR+ samples were tested by a cell cytotoxin assay (C. difficile Tox-B; TechLab), the more sensitive historical standard for C difficile toxin detection and diagnosis, to determine the number of samples that would have been positive if this test had been used instead of the toxin immunoassay. Culture was performed to recover C difficile isolates for ribotyping and verification of capacity to produce toxins. Lactoferrin was measured in PCR+ samples and random PCR− samples as a marker of inflammation (Leuko EZ Vue; TechLab; and IBD-Scan; TechLab). Lactoferrin results were classified as high if they exceeded the 95th percentile of results in PCR− patients. See the eMethods in the Supplement for additional details.
Clinical Data Collection
Diarrheal symptoms were verified at the time of C difficile testing. Patients were considered to have diarrhea if they had at least 3 unformed bowel movements or at least 600 mL of rectal or colostomy output recorded in the electronic health record (EHR) within 24 hours on the day of or before sample collection. 
Statistical Analysis
Baseline data were summarized and tested for differences. The Kruskal-Wallis test was used for continuous variables except for age, which was compared with an analysis of variance. For categorical variables, including outcomes, a χ 2 test or Fisher exact test was used. Kaplan-Meier estimates were used to show time to resolution of diarrhea for each group, with censoring of patients who were discharged or died during the followup, and compared with the log-rank test. A Cox proportional hazards model was used to estimate the effect of Tox+/PCR+ or Tox−/PCR+ status compared with Tox−/PCR− status on the duration of diarrhea, adjusting for age, comorbidities, ICU status on day 1 (±1 day), prior antibiotic days, prior metronidazole or oral vancomycin exposure, maximum white blood cell count on day 1 (±1 day), C difficile ribotype, and fecal lactoferrin level. See the eMethods in the Supplement for additional details.
Results
Patient Cohort and Baseline Characteristics
An overview of the study design, patient cohort, and follow-up is shown in Figure 1 . In total, 1416 hospitalized adults were analyzed, including 131 Tox+/PCR+ patients (9.3%), 162 Tox−/PCR+ patients (11.4%), and 1123 Tox−/PCR− patients (79.3%). The groups were similar in age, sex, number of comorbidities, nonantibiotic medication exposures, and proportions with leukopenia, renal insufficiency, and hypoalbuminemia except for fewer comorbidities in Tox−/PCR− patients ( Table 1 and eTable 2 in the Supplement). However, the Tox+/PCR+ group had more prior antibiotic exposure, more patients with leukocytosis, and more diarrhea on day 1. In feces, Tox+/PCR+ patients had an increased C difficile bacterial load, higher toxin concentration, and greater frequency of hypervirulent C difficile strain than Tox−/PCR+ patients. Correspondingly, Tox+/ PCR+ patients had significantly more fecal lactoferrin than Tox−/PCR+ patients, and 36.8% (43 of 117) had a lactoferrin level greater than the 95th percentile of Tox−/PCR− patients. In contrast, few Tox−/PCR+ patients (13.4% [19 of 142]) had a lactoferrin level above the 95th percentile of Tox−/PCR− patients, and 79.0% (15 of 19) of these patients had an alternative explanation for fecal inflammation, a previous diagnosis of CDI, or anti-C difficile treatment before testing (eTable 3 in the Supplement).
Duration of Diarrhea
The Tox+/PCR+ patients had a longer duration of diarrhea than Tox−/PCR+ patients and Tox−/PCR− patients (P < .001) and had a greater risk of diarrhea during the follow-up ( Figure 2 and Table 2 ). In contrast, Tox−/PCR+ patients and Tox−/PCR− patients had a similar risk of diarrhea on most days.
In the multivariable model, Tox+/PCR+ status had the strongest effect on duration of diarrhea, decreasing the probability of diarrhea being resolved by 37% each day relative to the Tox−/PCR− reference group (hazard ratio, 0.63; 95% CI, 0.48-0.83). Age, white blood cell count, and lactoferrin level were also significant predictors of duration of diarrhea, but their relative contribution was small (≤2% each) (eTable 4 in the Supplement). The Tox−/PCR+ status and pretest exposure to
CDI-Related Complications and Mortality Within 30 Days
The frequency of CDI-related complications (ie, megacolon, colectomy for fulminant colitis, and ICU care related to CDI) and deaths is summarized in Table 3 . The Tox+/PCR+ patients had more CDI-related complications than Tox−/PCR+ patients and Tox−/PCR− patients (10 [7.6%] of 131 vs 0 [0%] of 162 vs 3 [0.3%] of 1123, P < .001). In contrast, the rate of CDI-related complications was similar between Tox−/PCR+ patients and Tox−/PCR− patients (0% vs 0.3%, P > .99). The Tox+/PCR+ patients also had more CDI-related deaths than Tox−/PCR+ patients and Tox−/ PCR− patients (11 [8.4%] of 131 vs 1 [0.6%] of 162 vs 0 [0%] of 1123, P < .001) while the rate was similar between Tox−/PCR+ patients and Tox−/PCR− patients (0.6% vs 0%, P = .13). Two deaths in the Tox+/PCR+ group were directly attributable to CDI, and 9 had CDI as a contributing factor. One Tox−/PCR+ patient (patient 1641 in eTable 3 in the Supplement) had an uncomplicated, recurrent CDI that resolved before care was withdrawn for severe underlying illness, but CDI was considered a contributing factor to death.
Repeat C difficile Testing and Treatment Within 14 Days
Repeat C difficile testing and treatment within 14 days of day 1 was analyzed as an indication of ongoing clinical suspicion or empirical treatment for CDI in Tox−/PCR+ patients (Table 3) . During this period, 61 Tox−/PCR+ patients (37.7%) were retested, and 13 (8.0%) had toxins detected (mean time to positive result, 5.7 days; 95% CI, 3.2-8.2 days). None of these patients developed a C difficile-related complication. However, one patient (patient 1641 in eTable 3 in the Supplement) had CDI that was considered a contributing factor to death, although symptoms had resolved before care was withdrawn for other reasons. During the same period, most Tox−/PCR+ patients (59.3% 
Clostridium difficile Testing and Treatment Between 15 and 30 Days
Clostridium difficile tests and treatment 15 to 30 days after day 1 were analyzed as a proxy for recurrent or prolonged CDI (Table 3) . During this period, Tox+/PCR+ patients were retested almost twice as often as Tox−/PCR+ patients (19.8% vs 
Additional Analyses to Evaluate the Robustness of the Study Findings
Outcome differences between the Tox−/PCR+ and Tox+/PCR+ groups remained significant when comparisons were limited to the subgroup of Tox−/PCR+ patients who received full or partial treatment within 14 days (P = .04 for time to resolution of diarrhea and P = .004 for CDI-related complication or death) or no treatment (P = .003 for time to resolution of diarrhea and P < .001 for CDI-related complication or death). No significant outcome differences were observed between the Tox−/ PCR− group and individual Tox−/PCR+ subgroups with or without treatment.
If the historical cell cytotoxin assay had been used for diagnosis instead of a toxin immunoassay, 48 additional Tox−/ PCR+ patients (29.6%) would have been reported positive. However, this subgroup had a low toxin concentration (median, 10 ng/mL; interquartile range, 2-81 ng/mL) and outcomes that were similar to cell cytotoxin-negative Tox−/ PCR+ patients (P = .47 for time to resolution of diarrhea and P = .30 for CDI-related complication or death), with no difference in treatment (P = .61), and better than Tox+/PCR+ pa- Only one of 162 toxinnegative patients (0.6%) was considered to have CDI as a contributing factor to death. Our findings are consistent with the conventional view that CDI is a toxin-mediated inflammatory disease preceded by antibiotic exposure and C difficile overgrowth.
3 Toxin-negative patients had less antibiotic exposure, C difficile DNA, and inflammation and manifested milder symptoms and no complications, despite minimal or no treatment. These findings strongly suggest that most patients with negative toxin test results and C difficile detected by PCR do not need treatment for CDI. We suspect that most of these patients were colonized with C difficile and had another cause of diarrhea. This hypothesis is supported by studies [22] [23] [24] [25] [26] 31 showing that C difficile colonization and immunity are common in hospitalized patients and most nosocomial diarrhea is noninfectious. It is possible that some toxin-negative patients have mild or early infection because clinical toxin tests can miss toxin at low concentrations, and occasional toxin-negative patients become positive on repeat testing. Tox−/PCR+ patients retested positive by the clinical toxin immunoassay in a subsequent sample. However, the relative lack of adverse events in this subgroup suggests that these patients are also at lower risk of complications than clinical toxin immunoassay-positive patients and routine treatment is unnecessary. These results are consistent with a large retrospective study 36 that found no C difficile-related complications and lower mortality among hospitalized patients with negative toxin results. Our findings also agree with several smaller studies 11,14,37-41 and one large, multicenter study 21 that reported milder symptoms or a lower mortality rate in toxinnegative patients with positive PCR results. Other studies [42] [43] [44] [45] that have investigated clinical characteristics of Tox−/PCR+ patients were generally underpowered or not designed to compare outcomes. Finally, there are reports of patients with severe or complicated CDI missed by toxin tests, 43,46 but our data suggest that such patients are rare. Strengths of our study include the prospective study design, large sample size, nonreporting of PCR results, measurement of duration of diarrhea, inclusion of patients without C difficile for comparison, and rigorous evaluation of C difficilerelated complications and deaths. We quantified fecal C difficile DNA, toxins, and inflammation to provide mechanistic insight into the reasons for the different test results and outcomes. The primary weakness of the study was the inability to achieve equivalent risk allocation between groups. In addition, we cannot exclude the possibility that empirical treatment affected outcomes in some Tox−/PCR+ patients, but the outcome differences we observed remained when these patients were removed. It is also possible that our outcome adjudicators were influenced by positive toxin results, but 26 of 42 Tox+/PCR+ patients with ICU care or death (61.9%) were judged not to have a CDI-related outcome, indicating that the adjudication was a highly discriminatory process overall. Finally, we cannot exclude the possibility that systematic underrecording of stools in patients with negative toxin results could account for the shorter duration of diarrhea in these patients. However, our requirement of 2 or more days without diarrhea to end an episode would make it unlikely that underrecording by individual nurses would have a significant effect on our diarrhea measure.
Molecular tests have the potential benefits of decreasing the need for repeat testing and empirical treatment because respectively, for the 3 groups. P = .08 for all groups and P = .21 for Tox+/PCR+ vs Tox−/PCR+. For C difficile infection-related death, P < .001 for Tox+/PCR+ vs Tox−/PCR+ and P = .13 Tox−/PCR+ vs Tox−/PCR−. d Full treatment (Ն10 days) and partial treatment (1-9 days) values were 119 (90.8%) and 12 (9.2%), respectively; 21 (13.0%) and 45 (27.8%), respectively; and 82 (7.3%) and 279 (24.8%), respectively, for the 3 groups.
ever, our results offer compelling evidence that as many as half of the patients with positive C difficile PCR test results are likely to be overdiagnosed and exposed to unnecessary treatment at institutions using molecular tests. The number of patients potentially affected by this issue is massive. Most institutions experience a 50% to 100% increase in reported CDI after switching to molecular tests, and the proportion of institutions using molecular C difficile tests has increased dramatically since initiation in 2009 of the first FDA-approved molecular test. [11] [12] [13] [14] [15] In 2014, almost 44% of NHSN acute care facilities reported using molecular tests for CDI diagnosis (NHSN, written communication, September 15, 2014). Therefore, there is an urgent need to educate physicians that molecular tests are not specific for CDI, even in the presence of symptoms, and patients with positive PCR results do not necessarily need treatment. Similarly, while underdiagnosis may occur with lack of testing, 48 policy makers should be aware that molecular C difficile tests are a major cause of overdiagnosis and consider the potential costs of overtreatment in recommendations and analyses. Laboratories need to be aware that rejection of formed stool samples is not sufficient to ensure that all positive molecular C difficile results represent disease. We concur with authors in the United Kingdom that molecular tests should not be used as a stand-alone diagnostic test for CDI and diagnostic recommendations should move back in the direction of defining clinical disease as a positive toxin result in patients with diarrhea.
21,49 Most toxin-negative patients with C difficile do not need specific treatment, although there may be a role for identifying carriers to prevent transmission. 21, 43 Future studies should focus on developing diagnostic approaches to accurately distinguish patients with active infection vs colonization, which may include quantitation of C difficile DNA, toxins, or host response. In the meantime, 2-step testing with a screening test, such as PCR or glutamate dehydrogenase antigen detection, followed by a toxin test to confirm active infection is a reasonable diagnostic strategy.
21,49
Conclusions
Up to half of the patients with positive molecular test results for C difficile do not experience adverse events without treatment and do not need treatment for CDI. Exclusive reliance on molecular tests for C difficile diagnosis is likely to result in overdiagnosis, unnecessary treatment, and increased health care costs.
